Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells 70,384 Shares of Stock

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insider Neal Flomenberg sold 70,384 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $1.09, for a total value of $76,718.56. Following the completion of the transaction, the insider now directly owns 3,898,828 shares in the company, valued at $4,249,722.52. This represents a 1.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Neal Flomenberg also recently made the following trade(s):

• On Thursday, March 6th, Neal Flomenberg sold 88,519 shares of Tevogen Bio stock. The stock was sold at an average price of $1.10, for a total value of $97,370.90.
• On Tuesday, March 4th, Neal Flomenberg sold 14,639 shares of Tevogen Bio stock. The shares were sold at an average price of $1.28, for a total value of $18,737.92.

Tevogen Bio Stock Up 0.9 %

Shares of TVGN traded up $0.01 during midday trading on Tuesday, reaching $1.07. 363,430 shares of the stock were exchanged, compared to its average volume of 5,078,983. The firm has a 50 day simple moving average of $1.36 and a 200-day simple moving average of $1.17. Tevogen Bio Holdings Inc. has a 12-month low of $0.26 and a 12-month high of $6.95.

Hedge Funds Weigh In On Tevogen Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TVGN. Northern Trust Corp grew its position in Tevogen Bio by 13.0% in the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock worth $122,000 after acquiring an additional 13,595 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Tevogen Bio in the 4th quarter valued at $55,000. Barclays PLC boosted its holdings in Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after purchasing an additional 12,847 shares in the last quarter. Geode Capital Management LLC increased its position in Tevogen Bio by 31.2% during the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock worth $465,000 after buying an additional 107,566 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Tevogen Bio by 74.2% during the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock worth $40,000 after buying an additional 16,695 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Tevogen Bio in a report on Tuesday.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.